Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies

2011 ◽  
Vol 110 (3) ◽  
pp. 392-400 ◽  
Author(s):  
Con J. Kelleher ◽  
Roger R. Dmochowski ◽  
Sandra Berriman ◽  
Zoe S. Kopp ◽  
Martin Carlsson
Keyword(s):  
Overactive Bladder ◽  
Patient Reported Outcomes ◽  
Pooled Analysis ◽  
Open Label ◽  
Sustained Improvement ◽  
Overactive Bladder Symptoms ◽  
Patient Reported ◽  
Open Label Extension ◽  
Bladder Symptoms

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

2007 ◽  
Vol 23 (11) ◽  
pp. 2697-2704 ◽  
Author(s):  
Simon Hill ◽  
Mostafa Elhilali ◽  
Richard J Millard ◽  
Peter L Dwyer ◽  
Karine Lheritier ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Extension Study ◽  
Open Label ◽  
Open Label Extension ◽  
Analysis Of Results

Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: Open-label extension of the SOFIA trial

2013 ◽  
Vol 33 (1) ◽  
pp. 106-114 ◽  
Author(s):  
Adrian Wagg ◽  
Vik Khullar ◽  
Martin C. Michel ◽  
Matthias Oelke ◽  
Amanda Darekar ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Elderly Patients ◽  
Open Label ◽  
Open Label Extension ◽  
Flexible Dose

scholarly journals OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use

2017 ◽  
Vol 11 (5) ◽  
pp. 179 ◽  
Author(s):  
Kevin Carlson ◽  
Andrea Civitarese ◽  
Richard Baverstock
Keyword(s):  
Overactive Bladder ◽  
Patient Reported Outcomes ◽  
Efficacy And Safety ◽  
Clinical Registry ◽  
Safety Measures ◽  
Patient Reported ◽  
Before And After ◽  
Bladder Symptoms ◽  
Repeated Use ◽  
First Time

Introduction: The objective of this study was to compare efficacy and safety outcomes between patients receiving onabotulinumtoxinA (OnabotA) for the first time and those receiving a repeat injection.Methods: Data collected before and after OnabotA injection were extracted from a clinical registry. Patients were classified into either first or repeat injection subgroups. Efficacy was measured by the change in use of oral bladder medications, the number of voids per day or night, the frequency of urinary incontinence (UI) episodes, and patient-reported outcomes. Safety was measured by the number of self-reported complications. Differences in safety measures between the subgroups were tested.Results: The analysis included complete data from 81 patients; 30 (37%) receiving OnabotA for the first time, 51 (63%) receiving a repeat injection. Both subgroups reported significant reductions in the use of anticholinergics, more tolerable bladder symptoms, and improvements in patient-reported outcomes. Dry rates were similarly high in both groups (50% and 43%, respectively). There were no statistically significant differences between the subgroups in terms of their safety outcomes.Conclusions: OnabotA is equally as efficacious and safe for patients with overactive bladder receiving a repeat injection as it is for those receiving their first injection.

Sign in / Sign up

Export Citation Format

Share Document